Viral haemorrhagic fevers in nigeria
-
Upload
thomas-oricha -
Category
Health & Medicine
-
view
278 -
download
1
description
Transcript of Viral haemorrhagic fevers in nigeria
![Page 1: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/1.jpg)
VIRAL HAEMORRHAGIC
FEVERS IN NIGERIA
Dr. T. O. OrichaDept. Of Medicine
Federal Teaching Hosptal, Gombe
![Page 2: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/2.jpg)
Outline
• Introduction
• Epidemiology
• Pathogenesis
• Clinical features
• Differential diagnosis
• Diagnosis
• Management and Treatment
• Prevention
• Ebola virus disease
• Conclusion
• References
![Page 3: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/3.jpg)
Introduction
• Viral haemorrhagic fever (VHF) is a term first
coined by Russian physicians in the 1940s
• Syndrome of:
Fever
Constellation of initially nonspecific signs and
symptoms
Propensity for bleeding and shock
• Caused by more than 30 RNA viruses
![Page 4: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/4.jpg)
Introduction
• Pathogenic hallmarks:
Microvascular instability with capillary leak
Impaired haemostasis
• High case fatality rates
• Correct diagnosis depends on demonstration of the infecting virus or one of its products in acute serum samples
• Barrier nursing
• Avoidance of parenteral exposure
![Page 5: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/5.jpg)
Introduction
• 4 taxonomic families:
Filoviridae: Marburg, Ebola
Arenaviridae: Junin, Machupo, Guanarito, Sabia, Chapare, Lassa, Lujo
Bunyaviridae: Rift Valley fever, Crimean-Congo, Hantaan, Seoul, Puumala and others, Sin Nombre, Black Creek Canal, Bayou, Andes and others
Flaviviridae: Yellow fever, Dengue, KyasanurForest disease, Omsk HF, Alkhurma
![Page 6: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/6.jpg)
Introduction
• VHFs in Nigeria:
Yellow fever (YF)
Lassa fever (LF)
Dengue HF (DHF)
Ebola HF (EHF) / Ebola virus disease (EVD)
Marburg HF (MHF)
Crimean-Congo HF (CCHF)
Rift valley fever (RVF)
![Page 7: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/7.jpg)
Introduction
• Common characteristics of HF viruses.
Enveloped viruses with a ssRNA genome
Cytoplasmic replication
Pantropic targeting prim dendritic and
monocyte/macrophage cells
Sporadic outbreaks
Both genders and all age groups affected
![Page 8: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/8.jpg)
Introduction
Generally asymptomatic or flu-like symptoms
Severe cases associated with high levels of
virus in blood
Rodents/insects are natural reservoirs/vectors
Continuously emerging or re-emerging
Geographically restricted by presence of
natural host
![Page 9: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/9.jpg)
Epidemiology
![Page 10: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/10.jpg)
Epidemiology• Map showing cases/distribution of YF
![Page 11: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/11.jpg)
Epidemiology
![Page 12: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/12.jpg)
Epidemiology• LF: map of Nigeria 2012 and 2013 outbreaks
![Page 13: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/13.jpg)
Epidemiology• Reported outbreaks of LF, 16th March, 2012
![Page 14: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/14.jpg)
Epidemiology
• Geographic distribution of EHF outbreaks and
fruit bats of Pteropodidae family
![Page 15: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/15.jpg)
Epidemiology
• Geographic distribution of MHF outbreaks and
fruit bats of Pteropodidae family
![Page 16: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/16.jpg)
Epidemiology
![Page 17: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/17.jpg)
Epidemiology
• Geographic distribution of CCHF
![Page 18: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/18.jpg)
Epidemiology• Geographic distribution of RVF outbreaks
![Page 19: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/19.jpg)
Epidemiology
• Tomori et al; 1988
• Serosurvey for abs to viral agents with hemorrhagic febrile infections
• 1,677 human sera from different parts of Nigeria
• 357 (21.3%) +ve for Lassa
• 42 (2.5%) +ve for Rift valley
• 30 (1.8%) +ve for Ebola
• 29(1.7%) +ve for Marburg
• Abs to Lassa and RVF viruses were found in all locations in Nigeria
• EV and MV abs found mainly in northern savanna zones
![Page 20: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/20.jpg)
Epidemiology
• Olaleye et al; 1996
• 3,121 human sera from 6 ecological zones tested for presence of abs to RVF virus, 1985-1989
• 461 sera (14.8%) showed haemagglutination-inhibiting ab
• 390 of 461 reactive sera (84.6%) revealed neutralizing ab
• Of 461 sera tested for IgM, 107 gave +ve results (23.2%)
• Higher exposure among livestock workers/wild-life rangers
• Longitudinal study of 164 febrile pxs: infection rate 6.7%.
![Page 21: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/21.jpg)
Epidemiology
• 25 countries at risk of YF in Africa
• Nigeria among 18 affected
• West Africa worst hit; 13 of 14 countries
• Increased cases in West Africa linked to high non-immunized subjects.
• Bt 1984-1994, multifocal epidemics in Nigeria, 23,958 cases and 6,350 deaths.
• Cases reported 2000-2004 was 42
• As of 8 Feb. 2013, 38 suspected cases in 10 states
![Page 22: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/22.jpg)
Epidemiology• cases of YF reported in Nigeria, 1950-2004
![Page 23: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/23.jpg)
Epidemiology
• Carey et al; Aug 1964 to Dec 1968
• 32 strains of dengue virus were recovered from
febrile patients seen at UCH, Ibadan.
• 18 strains identified as dengue type 1
• 14 as dengue type 2.
• 1 April 2014, FMOH reported case of death
from DHF: 15-year old lady at Irrua Teaching
Hospital, Edo state.
![Page 24: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/24.jpg)
Epidemiology
• Idris A. N. et al; 2013
• Sero-prevalence of DENV-3 among 256
patients with febrile illnesses in UMTH
• 26 (10.1%) had neutralizing antibodies to
DENV-3
• Titres bt 1:10 and 1:320
![Page 25: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/25.jpg)
Epidemiology
Umoh et al; 1983
• Sera from 1164 cattles in north; 25.7% had
pptg abs against CHF-C virus
David-West TS et al; 1974
• A survey for neutralizing abs to Congo virus.
• Total sample population of 250: 141 males and
109 females
• 9 males and 15 females had +ve ab levels
![Page 26: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/26.jpg)
Epidemiology
• These viruses are zoonotic, maintained in
nature in mammals
• Exception of dengue virus, as humans are
considered to be reservoir
• Endemic area restricted by the distribution of
natural reservoir and/or arthropod vector
• Reservoir/vector to human
• Human to human
![Page 27: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/27.jpg)
Epidemiology
• Transmission to Humans
Inoculation into mucus membranes or broken skin of body fluids/feces
Mosquitoes or ticks
Aerosol transmission
Sexual transmission
• Large outbreaks almost always result of amplification in healthcare settings
• Risk of transmission during incubation period or from asymptomatic persons is negligible
![Page 28: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/28.jpg)
Epidemiology• Overview of the ecology and epidemiology of
these viruses
Disease Reservoir/Vector Distribution Clinical
cases/year
YF Monkey/mosquito (Aedes
aegypti, other Aedes spp.)
Sub-Saharan
Africa, South
America
5,000-200,000
LF Rodent (multimammate rat
or Mastomys Natalensis)
West Africa 30,000-50,000
EHF Fruit bat (Egyptian fruit bat
or Rousettus aegyptiacus);
non-human primates
West, Central, East
Africa
5-500
MHF Fruit bat (Egyptian fruit bat
or Rousettus
Aegyptiacus); non-human
primates
West, Central, East
Africa
5-300
![Page 29: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/29.jpg)
Epidemiology• Overview of the ecology and epidemiology of
these viruses
Disease Reservoir/Vector Distribution Clinical
cases/year
DHF Human/mosquito (Aedes
aegypti and albopictus)
Tropics and
subtropics
100,000-
200,000
CCHF Wild and domestic
vertebrates /tick (primarily
Hyalomma
Species)
Africa, Balkans,
South Russia,
Middle East, West
China etc
~500
RVF Domestic livestock/
mosquitoes (Aedes and
Others)
Sub-Saharan
Africa,
Madagascar, Saudi
Arabia, Yemen
100-100 000
![Page 30: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/30.jpg)
Epidemiology• Overview of the ecology and epidemiology of
these viruses
Disease Disease-to-
infection
Ratio
Case
fatality
Human-to-
Human
Transmissibility
Risk factors for
transmission
YF 1 : 2–20 20-50% No Not vaccinated.
Sporadic cases in
jungle, outbreaks in
semi-humid
savannah
LF 1 : 5–10 10-25% Moderate Contact with rodents
and their excreta
EHF 1 : 1 25-90% High Contact with caves
or diseased primates
MHF 1 : 1 25-90% High Contact with caves
or diseased monkeys
![Page 31: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/31.jpg)
Epidemiology• Overview of the ecology and epidemiology of
these viruses
Disease Disease-to-
infection
Ratio
Case
fatality
Human-to-
Human
Transmissibility
Risk factors for
transmission
DHF 1 : 10–100 Untreated:
10-15%
Treated:<
1
None Crowded
population; bad
water, sewage waste
systems
CCHF 1 : 1–2 15-30% High Contact with blood
of diseased animals
(ruminants)
RVF 1 : 100 10–50% None Epizootics of
ruminants. Contact
with animal blood
![Page 32: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/32.jpg)
Pathogenesis• Viral properties
Virus Virus family Physical
Type of
Nucleic
Acid
Virus
Particle
Size
(nm)
Size of
Nucleic
Acid
in Virion
(kb/kbp)
Gene products
YF Flaviviridae ss +ve
sense
RNA
40-60
spheroidal
10.9 3 structural proteins:
capsid, premembrane, and
envelope
7 non-structural
proteins: NS1, NS2A,
NS2B, NS3, NS4A,
NS4B, NS5
LF Arenaviridae ss bi-
segment
ed
ambisen
se RNA
110-130
round,
oval, or
pleomorp
hic
10-19 Large segment: Zn-
binding protein, RNA
polymerase
Small segment:
nucleoprotein, surface GP
precursor
![Page 33: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/33.jpg)
Pathogenesis• Viral properties
E Filoviridae ss –ve
sense
RNA
800-1100
Cylindrical
or
tubular
18-19 Nucleoprotein,
polymerase
Cofactor, matrix protein,
sGP, Δ-peptide, GP1,2,
transcription activator,
secondary matrix protein,
RNA-dependent
RNA polymerase
M Filoviridae ss –ve
sense
RNA
800-1100
Cylindrical
or
tubular
18-19 Nucleoprotein,
polymerase
Cofactor, matrix protein,
GP1,2, transcription
activator, secondary
matrix protein, RNA-
dependent
RNA polymerase
![Page 34: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/34.jpg)
Pathogenesis• Viral properties
D Flaviviridae ss +ve
sense
RNA
40-65
spherical
11 3 structural proteins
7 non-structural proteins
CCHF Bunyaviridae ss –ve
sense,
ambisens
e triple
segment
d RNA
80–120
spherical
or
pleomor
phic
L(11-
14.4)
M(4.4–
6.3)
S(1.7–2.1)
L segment: RNA
polymerase
M segment: envelope
proteins (Gc, Gn)
S segment: nucleocapsid
protein
RVF Bunyaviridae ss –ve
sense,
ambisens
e triple
segment
d RNA
90-110
spherical
or
pleomor
phic
L(6.6)
M(3.9)
S(1.7)
L segment: RNA
polymerase
M segment: 2 SPs (Gc,
Gn), 2 NSPs (78 kDa
and 14 kDa NSm
protein)
S segment: structural
nucleoprotein, small
NSP
![Page 35: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/35.jpg)
PathogenesisInfection
Dendritic cells/Macrophages
Draining lymph nodes (Replication)
Tissue invasion
Bloodstream (Dissemination)
Inflammatory cells
Vasoactive mediators (TNF-α, NO, MCP-1)
Recovery
Capillary endothelial cell permeabilty
Plasma leakage/haemorrhage/shock
Recovery Death
Tissue damage (liver, kidney)
Viraemia
Secondary viraemia
![Page 36: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/36.jpg)
Pathogenesis
![Page 37: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/37.jpg)
Pathogenesis
![Page 38: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/38.jpg)
Pathogenesis• Mechanism of endothelial dysfunction
![Page 39: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/39.jpg)
Pathogenesis• Summary of pathogenesis of VHFs
![Page 40: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/40.jpg)
Pathogenesis
• Major pathogenic mechanisms
Depletion of hepatic coagulation factors
Cytokine storm (TNF-α, IL-10, IL-1Ra, TRAIL, etc)
Increased vascular permeability
Complement activation, and DIC
Impaired innate immune response from non-lytic
viral replication
Thrombocytopenia & Inhibition of Platelet Fn.
![Page 41: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/41.jpg)
Pathogenesis• Pathogenic mechanisms proposed for VHFs
Virus Leukopenia/
Immunesuppr
ession
Thromboc
ytopenia
Platelet
altered
function
Reduced
coagn
factors
DIC Endothelial
dyfn
YF + + ? + + +LF + +/N + - - +EHF + + + + + +MHF + + + + + +DHF + + + + + +CCHF + + ? + + +RVF + + ? + + +
![Page 42: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/42.jpg)
Pathogenesis
• Pathobiological and Clinical Aspects of VHFs
VHF I.P
(day
s)
Onset Blee
ding
Rash Jaundi
ce
Heart Lung Kidney CNS Eye
YF 3-6 Abrupt +++ 0 +++ ++ + ++ ++ 0
LF 5-16 Gradual + + 0 ++ + 0 + 0
EHF 2-21 Abrupt ++ +++ + ++ + + + +
MHF 2-21 Abrupt ++ +++ + ++ + + + +
DHF 3-15 Abrupt ++ +++ + ++ + 0 + 0
CCHF 3-12 Abrupt +++ 0 ++ + + 0 + 0
RVF 2-5 Abrupt ++ + ++ + 0 + ++ +
![Page 43: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/43.jpg)
Pathogenesis• Natural history
![Page 44: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/44.jpg)
Clinical features
• Spectrum from mild or asymptomatic infection
to severe vascular permeability with shock,
multi-organ system failure and death
• Clinical presentation may differ for each viral
HF as it progresses
• Distinct phases of disease and recovery
• Biphasic illnesses with quiescent period of
days (YF and DHF)
![Page 45: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/45.jpg)
Clinical features
Incubation period days to weeks
Fever and
Constitutional symptoms:
• General malaise
• Anorexia
• Headache
• Myalgia
• Arthralgia
• Sore throat
• Chest or retrosternal pain and lumbosacral pain
![Page 46: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/46.jpg)
Clinical features
GIT features: Nausea/Vomiting, Abdominal pain/tenderness, Diarrhoea (may become bloody in later stages), Constipation
Conjunctival injection/haemorrhage
Skin rash: Morbilliform, Maculopapular, Petechial, Ecchymotic
Orthostatic hypotension
Neck pain/stiffness, retro-rbital pain/photophobia (RVF)
![Page 47: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/47.jpg)
Clinical features
End of first week (vascular instability)
Facial flushing
Oedema
Bleeding
Haematemesis, melena/haematochezia, metrorrhagia, petechiae, purpura, epistaxis, bleeding from gums, venepuncture sites
Internal bleeding from GIT
Haemoptysis and haematuria are infrequent
Hypotension/shock
Proteinuria
![Page 48: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/48.jpg)
Clinical features
CNS manifestations (end-stage disease)
• Disorientation
• Tremor
• Gait anomalies
• Convulsions
• Hiccups
Renal failure (end-stage disease)
Spontaneous abortion/vaginal bleeding, maternal/fetal mortality ~100% in 3rd trimester
![Page 49: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/49.jpg)
Clinical features
• Persistent myalgia
• Arthralgia
• Anorexia
• Weight loss
• Alopecia
• Orchitis
• Irritability
• Memory changes
No permanent sequelae
in most cases
Depression
Post-traumatic stress
Social stigmatization
Convalescence (up to a year)
![Page 50: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/50.jpg)
Differential diagnosis
• Initial misdiagnosis of more familiar
syndromes is common
• Malaria and bacterial septicaemia, most
common
• Possibility of co-infection should be
considered
![Page 51: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/51.jpg)
Differential diagnosis
• Features making VHF less likely:
o Haemorrhage in the first few days of illness
o Conjunctival injection/sub-conjunctival
haemorrhage accompanied by itching
o Jaundice on presentation (except YF)
o Prominent pulmonary symptoms
o Response to antibiotics
![Page 52: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/52.jpg)
Differential diagnosis
Viruses:
• Inluenza
• Viral hepatitis (hp.A, B, E, EBV and CMV)
• Herpes simplex or varicella-zoster (fulminant)
• HIV/AIDS
• Measles
• Rubella
• Haemorrhagic or flat smallpox
• Alphavirus infection (chikungunya, o’nyong-nyong)
![Page 53: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/53.jpg)
Differential diagnosis
Bacteria:
• Typhoid fever
• Bacillary dysentery
• Meningococcaemia
• Staphylococcaemia
• Septic abortion
• Septicaemic plague
• Streptococcal pharyngitis
• PTB (advanced)
• Acute abd. emergencies
• Tularaemia
• Pyelonephritis
• Post-infectious GN
• Anthrax (inhalation or GI)
• Relapsing fever
• Leptospirosis
• Rickettsia
• Q fever
• Ehrlichiosis
![Page 54: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/54.jpg)
Differential diagnosis
Parasites:
• Malaria
• Amoebiasis
• Giardiasis
• African tripanosomiasis
(acute stages)
Non-infectious
• Heat stroke
• ITP/TTP
• Acute glaucoma
• Haem. malignancies
• Drug sensitivity/overdose
• Chemical poisoning
• Haematoxic snake bite
envenomation
![Page 55: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/55.jpg)
Diagnosis
Clinical Diagnosis
Laboratory Diagnosis
Case Definition
![Page 56: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/56.jpg)
Diagnosis
Clinical Diagnosis
History of illness
Detailed epidemiological history
Physical examination
Preliminary basic laboratory results
![Page 57: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/57.jpg)
Diagnosis
Clinical Diagnosis
Clinically compatible syndrome
Fulfills any epidemiologic linkage criteria
• High index of suspicion for persons in high-risk occupations: abattoir workers, veterinarians, farm workers/hunters/taxidermists.
• Acts of bioterrorism must be considered
• Alternative diagnoses should always be aggressively sought
![Page 58: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/58.jpg)
Diagnosis
• Wbc & diff; ESR
• Hb/Hct
• Platelet count
• BUN/creatinine
• AST, ALT, lactate
• Blood gas
• Coagn studies (PT/PTT,
fibrinogen, FDP, D-dimer)
• Urinalysis
• Blood culture
• Stool culture
• Thick/thin blood smears
• Rapid test for malaria
• Assay for Salmonella
• Indicated Clinical Laboratory Tests
![Page 59: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/59.jpg)
Diagnosis
Laboratory Diagnosis
• VHF still suspected after initial work-up/lab tests
• Specialized laboratory testing
ELISA
RT-PCR
Cell culture
IFA
Immunohistochemical staining of formalin-fixed tissue: skin, liver, spleen (Post-mortem diagnosis)
![Page 60: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/60.jpg)
Diagnosis
Laboratory Diagnosis
• No test can reliably diagnose VHF before onset of illness
• Test of contacts/asymptomatic persons not recommended
Acute febrile stage
• Identify virus/virus antigen/nucleic acid
• Prognostic value
• Samples: serum, throat washings, urine, CSF, breast milk
ELISA antigen tests
RT-PCR
Multiplex PCR assays
Cell culture (high containment facility; 2–10 days)
![Page 61: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/61.jpg)
Diagnosis
o False negative
Limitations: of the various lab assays
Inhibitory substances in the blood
• Repeat in 1-2 days and, if necessary, again in convalescence, if high clinical suspicion
• Discard diagnosis if virus, antigen or nucleic acid cannot be detected during first 7 days of illness and IgM is negative
o False-positive
![Page 62: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/62.jpg)
Diagnosis
Laboratory Diagnosis
Sub-acute and convalescent stages
• IgM antibody (sub-acute stage)
• IgG antibody (convalescent stage)
• ELISA or IFA
• Antibody seroconversion (4-fold increase in
titre) retrospectively diagnose acute disease
![Page 63: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/63.jpg)
Diagnosis
Case Definition
2011 Case Definition
Clinical Criteria
Laboratory Criteria
Epidemiologic Linkage
![Page 64: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/64.jpg)
Diagnosis
Fever >40°C
One or more of:Severe headache
Muscle pain
Erythematous maculopapular
rash on trunk with fine
desquamation after 3-4 days
Vomiting
Diarrhea
Pharyngitis (LF)
Abdominal pain
Bleeding unrelated to injury
Retrosternal chest pain (LF)
Proteinuria (LF)
Thrombocytopenia
Clinical Criteria• Illness with ACUTE ONSET with:
![Page 65: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/65.jpg)
Diagnosis
Laboratory Criteria• One or more of:
Detection of VHF viral antigens in blood by ELISA antigen detection
VHF viral isolation in cell culture of blood/tissues
Detection of VHF-specific genetic sequence by RT-PCR from blood or tissues
Detection of VHF viral antigens in tissues by immunohistochemistry
![Page 66: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/66.jpg)
Diagnosis
Epidemiologic Linkage• One or more of the following exposures within 3wks:
Contact with blood/body fluids of VHF px
Residence in/travel to VHF endemic area
Work in lab that handles VHF specimens
Work in lab that handles bats, rodents, primates from endemic areas
Exposure to semen of confirmed acute/convalescent case of VHF in 10wks of the person's symptom onset
![Page 67: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/67.jpg)
Diagnosis
o Case Classification
• Suspected
Clinical criteria
Epidemiologic linkage criteria.
• Confirmed
Clinical criteria
Laboratory criteria.
![Page 68: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/68.jpg)
Management and Treatment
• Routine universal precautions
• Consultation with infectious disease specialists or clinicians with experience when diagnosis is suspected
• When to ‘sound the alarm’ of VHF is case-by-case decision
• All cases of confirmed VHF should be reported to
o Government health authorities
o WHO
![Page 69: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/69.jpg)
Management and Treatment
• In Nigeria
Access to basic lab tests for broad range of dx
in diff. dx of VHF is limited
Empiric treatment to cover usual range of
infectious agents
Admission to isolation ward based on
nonspecific clinical/epidemiological features
On-site specialized diagnostics advocated
![Page 70: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/70.jpg)
Management and Treatment
General supportive measures
Antiviral drugs
Antibody therapy
Immune modulators
Coagulation modulators
Management of convalescence
![Page 71: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/71.jpg)
Management and Treatment
General supportive measures
Fluid Management
• Aggressive fluid replacement
Crystalloids (Ringers lactate or normal saline)
Vasopressors (dopamine or norepinephrine) to maintain CVP bt 8-12 mmHg or MAP >65 mmHg in adults
Dobutamine
Peritoneal/haemo-dialysis (renal syndrome)
![Page 72: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/72.jpg)
Management and Treatment
Blood Products and Management of DIC
Packed rbc to maintain Hct > 30%
Platelet concentrate (1-2 U/10 kg) if platelet count <50,000/µL (<20 000/µL without bleeding)
FFP (15-20 mL/kg) if bleeding is present & fibrinogen levels <100mg/dL
Fibrinogen concentrates (total dose 2-3g) or cryoprecipitates (1U/10 kg)
VitK if underlying malnutrition or liver dx
![Page 73: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/73.jpg)
Management and Treatment
Antibiotics and/or antiparasitics
Pain control and ulcer prophylaxis
Management of seizures
Nutrition
Management of pregnant patients
Uterine evacuation (extreme caution)
Lab parameters should be monitored closely
![Page 74: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/74.jpg)
Management and Treatment
Antiviral drugs
Ribavirin
• Guanosine analogue
• Lethal mutagenesis
Efficacious in treatment of LF
Used for CCHF
• Not efficacious for EHF/MHF
![Page 75: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/75.jpg)
Management and Treatment• Ribavirin Therapy
Indication Route Dose Interval
Treatment IV
IV
IV
30mg/kg
(max.2g)
15mg/kg
(max.1g)
7.5mg/kg
(max.500mg)
Loading dose, followed by:
Every 6hrs for 4days,
followed by:
Every 8hrs for 6days
Prophylaxis PO
PO
35mg/kg
(max.2.5g)
15mg/kg
(max.1g)
Loading dose, followed by:
Every 8hrs for 10days
![Page 76: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/76.jpg)
Management and Treatment
Ribavirin
• Side-effect: haemolytic anaemia
• Contraindications (relative)
o Severe anaemia or haemoglobinopathy
o CAD
o Renal insufficiency
o decompensated liver disease
o breast-feeding
o Known hypersensitivity
o Pregnancy
Other antiviral drugs (Experimental therapies)
![Page 77: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/77.jpg)
Management and Treatment
Antibody Therapy
• Severe/refractory cases when ribavirin is not
an option
Immune Modulators
• Corticosteroids if adrenal insufficiency
Coagulation Modulators (experimental)
![Page 78: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/78.jpg)
Management and Treatment
Abstinence/condom use
for 3 months
Separate toilet facilities
Regular hand-washing
Avoid breast-feeding
Warm packs
Acetaminophen/NSAID
Cosmetics; hair-growth
stimulants
Anxiolytics/antidepressants
Nutritional supplements
Psychological counselling
Management of Convalescence
![Page 79: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/79.jpg)
Prevention
Patient isolation
Personal Protective Equipment (PPE)
Nursing precautions
Contact tracing
Post-exposure prophylaxis
Environmental shedding and disinfection
Vaccines
Reservoir/vector control
![Page 80: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/80.jpg)
Ebola virus disease
• First appeared in 1976 in 2 villages in Central Africa, the 2nd near Ebola river
• Index case 2yr-old boy Emile died on 6 Dec.2013, Guinea.
• WHO reported outbreak: 25, March 2014
• Countries affected: Nigeria, Senegal, Guinea, Liberia, Sierra Leone, US, Spain.
• By 14th October, 2014:
9,216 suspected cases; 4,555 deaths
4,995 cases; 2,729 deaths lab confirmed
• Average case fatality rate: 50%
![Page 81: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/81.jpg)
Ebola virus disease
Country reports fall into 2 categories:
Widespread and intense transmission (Guinea,
Liberia, and Sierra Leone)
Initial case/cases, or localized transmission
(Nigeria, Senegal, Spain, USA)
• On August 8, WHO Director-General declared
this outbreak a Public Health Emergency of
International Concern
![Page 82: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/82.jpg)
Ebola virus disease
• 20 July, 2014 first case in Nigeria Patrick
Sawyer (from Liberia); died, July 25.
• Cases in Nigeria
• Case fatality rate: 40%
• 891 contacts have now completed 21-day
follow-up (362 in Lagos, 529 in Port Harcourt)
CASE DEFINITION CASES DEATHS
Confirmed 19 7
Probable 1 1
Suspected 0 0
All 20 8
![Page 83: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/83.jpg)
Ebola virus disease
5 species:
• Zaire ebolavirus (1976) - in present outbreak
• Sudan ebolavirus (1976)
• Côte d'Ivoire ebolavirus (1994; also known as
Tai Forest ebolavirus)
• Reston ebolavirus (1994)
• Bundibugyo ebolavirus (2007)
![Page 84: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/84.jpg)
Ebola virus disease• Life cycle of the Ebolavirus
![Page 85: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/85.jpg)
Ebola virus disease
Viral Proteins
Nucleoprotein (NP)
Polymerase cofactor (VP35)
Matrix protein (VP40)
soluble GP (sGP), GP1,2
Transcription activator (VP30)
Secondary matrix protein (VP24)
RNA-dependent RNA polymerase (L)
![Page 86: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/86.jpg)
Ebola virus disease
• Entry via: conjunctiva and oropharynx, or injured skin, eating of freshly killed bats
• Extensive replication in lymph nodes, spleen, liver
GP1,2-mediated entry mechanisms:
Endocytosis
Macropinocytosis
sGP:
Anti-inflammatory
Endothelial barrier protector function
Induces cytopathic effects
![Page 87: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/87.jpg)
Ebola virus disease
GP1,2 and VP40
Activate endothelial cells to express ICAM-1, VCAM-1, and E-selectin
Induce macrophages to secrete TNF-α, IL-6, IL-8, GPO-α
VP35 and VP24 inhibit IFN activity
• EV inhibits dendritic cell maturation/cytokine production, with reduced T cell proliferation
• Decreased CD4/CD8 T lymphocytes by apoptosis mediated by Fas/FasL
![Page 88: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/88.jpg)
Ebola virus disease
• Multifocal necrosis occurs most severely in
liver, spleen, kidneys, testes, and ovaries
• Survivors develop IgG mainly against NP
early, and VP40
• Thereafter cytotoxic T cells are activated
• Terminally ill patients never develop IgG and
only 1/3 mount weak IgM response
![Page 89: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/89.jpg)
Ebola virus disease• Replication cycle of EV
![Page 90: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/90.jpg)
Ebola virus disease
• Clinical features
• Incubation period: 5 days (2-21 days)
Early features
Sudden onset fever, headache, myalgia, sore throat, extreme fatigue
Conjunctivitis
Relative bradycardia
Nausea/vomiting, abdominal pain and watery diarrhea
Perifollicular, non-itching, maculopapular rash (5th day)
![Page 91: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/91.jpg)
Ebola virus disease
Haemorrhagic manifestations (5-7th day), in ˂50%:
Epistaxis/gum-bleeding
Haematemesis/melaena
Petechiae/ecchymoses
Haemorrhages from needle sticks
Visceral haemorrhagic effusions
Dehydration, prostration; ghost-like facial expression
Hepatosplenomegaly, oedema, orchitis, scrotal/labial reddening, myocarditis and pancreatitis
![Page 92: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/92.jpg)
Ebola virus disease
Poor prognosis is marked by:
Haemorrhagic signs
Oliguria/anuria; shock
Tachypnoea
Neurological symptoms: confusion or coma
Death due to shock occurs 6-9 days after onset
Abortion is a common consequence
Recovery may last for wks: weakness, arthralgia, uveitis, orchitis, hearing loss
![Page 93: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/93.jpg)
Ebola virus disease
• Oral bleeding • Rectal bleeding
![Page 94: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/94.jpg)
Ebola virus disease
Other Lab. findings
• Low wbc
• Low platelet count
• Prolonged PT/aPTT
• Low fibrinonogen
• High FDP
• High liver enzymes
• Renal failure
Diagnosis
• RT-PCR assay
• Antibody-capture ELISA
• Antigen-capture detection tests
• Serum neutralization test
• Electron microscopy
• Cell culture.
• No test can detect infection in incubation period
![Page 95: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/95.jpg)
Ebola virus disease• Case classification criteria
CLASSIFICATION CRITERIA
Suspected Sudden onset of high fever and contact; or
Sudden onset of high fever and at least 3 of:
headache, vomiting, anorexia, diarrhoea,
lethargy, abdominal pain, muscle/joint
aches, difficulty swallowing, breathing
difficulty, or hiccup; or
Any person with unexplained bleeding; or
Sudden, unexplained death
Probable Suspected case or death from suspected EVD
with epidemiological link to confirmed case but
no lab confirmation
Confirmed Probable or suspected case with lab confirmation
Non-case Suspected or probable case with a -ve lab result
![Page 96: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/96.jpg)
Ebola virus disease
Management
• Isolation
• No specific antiviral therapy
• Supportive care
Rehydration with oral or intravenous fluids
Treatment of specific symptoms
• Activated protein C (experimental)
• rNAPc2 (completed phase 1 trial)
![Page 97: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/97.jpg)
Ebola virus disease
o PEP and vaccine
(undergoing trials)
Vesicular stomatitis
virus vectored vaccine
DNA plasmid vaccine
• Proper case management
• Surveillance
• Contact tracing
• Good laboratory service
• Safe burials
• Social mobilisation
Prevention and control
![Page 98: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/98.jpg)
Ebola virus disease
Focus of risk reduction measures
Reducing risk of wildlife-to-human transmission
Reducing risk of human-to-human transmission
Outbreak containment measures
Controlling infection in health-care settings
WHO response
Nigeria response
![Page 99: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/99.jpg)
Conclusion
• VHFs are emerging infectious dxs caused by ssRNA viruses belonging to 4 families
• 7 have been shown to be present in Nigeria either by case identification or serological evidence
• They cause uniformly severe infections with high fatality rates to mostly asymptomatic infections
• Hallmark is vascular instability
• Important to spot due to public health implications
• Minimizing contact is essential
• Nigeria successfully contained EVD
• Efforts must continue to prevent re-emergence in the country and to contain the disease in worst hit areas
![Page 100: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/100.jpg)
THANK YOU
FOR LISTENING
![Page 101: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/101.jpg)
References
• David Mabey et al, Principles of Medicine in Africa, 4th Edition; 2013; Ch.34
• Jeremy Farrar et al; Manson’s Tropical Diseases, 23rd Edition; 2014; Ch.16
• http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/viral-hemorrhagic-fevers
• https://www.gov.uk/lassa-fever-origins-reservoirs-transmission-and-guidelines; Lassa fever: map of Nigeria 2012 and 2013 outbreaks
• WHO. International Travel and Health: Situation as on 1 January 2010. Geneva: WHO; 2010; Appendix 1a: Yellow Fever countries at risk, 2008
• http://www.flutrackers.com/forum/showthread.php?t=181234; reported outbreaks of Lassa fever as of 16th March, 2012
• http://www.cdc.gov/vhf/lassa/resources/distribution-map.html
• http://www.health.gov.ng/index.php/news-media/9-uncategorised/162-health-minister-debunks-outbreak-of-ebola-virus-in-nigeria-says-is-dengue-fever
![Page 102: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/102.jpg)
References
• Daily Trust (Abuja) 2 APRIL 2014Nigeria: Govt - We Have Case of Dengue Fever, Not Ebola Virus
• Umoh et al; Prevalence of antibodies to Crimean haemorrhagic fever-Congo virus in cattle in northern Nigeria; Int. J. Zoonoses. 1983, Dec; 10(2):151-4
• Tomori O et al; The American journal of tropical medicine and hygiene;1988 Mar; 38(2): 407-10. Viral hemorrhagic fever antibodies in Nigerian populations. OLALEYE et al; Rev. sci. tech. Off. int. Epiz., 1996,Sept. 15(3),923-935; Rift Valley fever in Nigeria: infections in humans
• Oyewale Tomori; Rift valley fever virus infection in man in Nigeria; Journal of Medical Virology; Volume 5, Issue 4, pages 343–350, 1980
• Overview of the epidemiological situation of yellow fever in Africa; The yellow fever situation in Africa and South America in 2004, Weekly Epidemiological Record. Vol. 80, 29, 2005 249–256; http://www.who.int/wer
• Epidemiological data 2000-2004; http://www.who.int/csr/disease/yellowfev/surveillance/en/#figures
![Page 103: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/103.jpg)
References
• http://www.thetraveldoctor.com/nigeria-medical-alert; CASES OF YELLOW FEVER IN NIGERIA, Mar 01, 2013
• D. E. Carey et al; DENGUE VIRUSES FROM FEBRILE PATIENTS IN NIGERIA, 1964-68; The Lancet, Volume 297, Issue 7690, Pages 105 -106, 16 January 197
• David-West TS et al, (1974); Seroepidemiology of Congo virus (related to the virus of Crimean haemorrhagic fever) in Nigeria. Bull WHO 51: 543-546
• Idris A. N. et al; Sero-prevalence of dengue type-3 Virus among patients with febrile illnesses attending a tertiary hospital in Maiduguri, Nigeria; International Journal of Medicine and Medical Sciences; Vol. 5(12), pp. 560-563, December 2013
• http://ci.vbi.vt.edu/pathinfo/pathogens/Rift_Valley_Fever_virus.html
• http://vhfc.org/lassa_fever/virology
• Pathogenesis of the Viral Hemorrhagic Fevers, Annual Review of Pathology: Mechanisms of Disease; 2013; Vol. 8: 411-440
• https://microbewiki.kenyon.edu/index.php/Infection Mechanism of Genus Ebolavirus
![Page 104: Viral haemorrhagic fevers in nigeria](https://reader033.fdocuments.net/reader033/viewer/2022052906/558a25f8d8b42a10248b4754/html5/thumbnails/104.jpg)
References
• www.medscape.com/Clinical Aspects of Marburg Hemorrhagic Fever; Pathology & Pathophysiology; fig.3: Marburg hemorrhagic fever pathogenesis model
• http://wwwn.cdc.gov/ National Notifiable Diseases Surveillance System (NNDSS); 2011 Case Definition
• http://en.wikipedia.org/wiki/File:EbolaCycle.png
• http://virologytidbits.blogspot.com/2014/03/Molecular aspects of Ebola and other Filoviruses
• WHO: EBOLA RESPONSE ROADMAP UPDATE; 17, October, 2014
• http://www.who.int/mediacentre/factsheets/fs103/en/Ebola virus disease; September, 2013
• http://wwwnc.cdc.gov/travel/notices/watch/ebola-nigeria
• http://en.wikipedia.org/wiki/Ebola virus epidemic in West Africa